InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Drawdown of $3.5m Convertible Note 23 Nov 2020 8:16PM $0.022 $0.420 risen by 1,809.09%
$18 MGC PHARMA COMPLETES ACQUISITION OF TELEHEALTH PLATFORM MCC 23 Nov 2020 2:59PM $0.022 $0.420 risen by 1,809.09%
$18 FURTHER SUCCESSFUL RESULTS FROM GLIOBLASTOMA RESEARCH 17 Nov 2020 10:09AM $0.022 $0.420 risen by 1,809.09%
$18 Conversion of Convertible Notes - Appendix 2A 13 Nov 2020 4:31PM $0.021 $0.420 risen by 1,900%
$18 COMPLETION OF PHASE II CLINICAL TRIAL ON COVID-19 PATIENTS 5 Nov 2020 9:17AM $0.020 $0.420 risen by 2,000%
$18 Constitution 4 Nov 2020 8:11PM $0.020 $0.420 risen by 2,000%
$18 Results of Annual General Meeting 4 Nov 2020 8:06PM $0.020 $0.420 risen by 2,000%
$18 AGM Presentation 4 Nov 2020 3:11PM $0.021 $0.420 risen by 1,900%
$18 Annual Report 2020 28 Oct 2020 11:30AM $0.022 $0.420 risen by 1,809.09%
$18 MGC Pharma AGM Information and Webinar 28 Oct 2020 8:13AM $0.022 $0.420 risen by 1,809.09%
$18 September Quarterly Activity and Cashflow Report 27 Oct 2020 9:51AM $0.022 $0.420 risen by 1,809.09%
$18 Unmarketable Parcel Share Sale Update 26 Oct 2020 3:50PM $0.023 $0.420 risen by 1,726.09%
$18 MGC PHARMA DELIVERS RECORD CONSECUTIVE WEEKLY SALES GROWTH 20 Oct 2020 9:37AM $0.023 $0.420 risen by 1,726.09%
$18 ARTEMIC HISTOLOGY ON RATS CONFIRM NO PATHOLOGICAL IMPACT 14 Oct 2020 12:53PM $0.024 $0.420 risen by 1,650%
$18 FIRST HIGH THC PRODUCTS SHIPPED DIRECT TO BRAZIL PATIENTS 12 Oct 2020 8:13AM $0.023 $0.420 risen by 1,726.09%
$18 MGC PHARMA LAUNCHES CANNEPIL APP 7 Oct 2020 9:21AM $0.022 $0.420 risen by 1,809.09%
$18 Letter to Shareholders - Upcoming Annual General Meeting 2 Oct 2020 1:41PM $0.023 $0.420 risen by 1,726.09%
$18 Notice of Annual General Meeting/Proxy Form 2 Oct 2020 1:40PM $0.023 $0.420 risen by 1,726.09%
$18 Appendix 4G and Corporate Governance Statement 1 Oct 2020 8:03AM $0.023 $0.420 risen by 1,726.09%
$18 Annual Report for the year ended 30 June 2020 1 Oct 2020 8:03AM $0.023 $0.420 risen by 1,726.09%
$18 UPDATE ON ARTEMIC PHASE II TRIAL ON COVID-19 PATIENTS 28 Sep 2020 9:41AM $0.023 $0.420 risen by 1,726.09%
$18 MXC WELCOMES NEW FCA GUIDANCE FOR CANNABIS SECTOR IN THE UK 21 Sep 2020 8:18AM $0.023 $0.420 risen by 1,726.09%
$18 Issue of Securities - Appendix 2A 15 Sep 2020 1:39PM $0.024 $0.420 risen by 1,650%
$18 MXC WELL POSITIONED FOR TGA DOWN-SCHEDULE OF CBD PRODUCTS 14 Sep 2020 9:20AM $0.023 $0.420 risen by 1,726.09%
$18 Prospectus 10 Sep 2020 5:21PM $0.024 $0.420 risen by 1,650%

376 - 400 of 818 results

Page 16 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.